TABLE 3.
Summary of moxifloxacin treatment outcomes by single nucleotide polymorphisms in parC
| parC SNP | Amino acid change | No. of cases with specific SNP who had treatment failure/total no. of cases with each SNP treated with moxifloxacin for study group: |
Overall analysis |
|||
|---|---|---|---|---|---|---|
| 2012–2013 (n = 54) | 2016–2018 (n = 201)a,b,c | 2019–2020 (n = 164) | No. of cases with specific SNP who had treatment failure/total no. of cases with each SNP treated with moxifloxacin (%) (n = 381) | 95% CI | ||
| A247C/T249G | S83R | 2/2 | 0/3 | 1/1 | 3/6 (50.0) | 11.8–88.2 |
| G248T | S83I | 4/7 | 16/30 | 24/38 | 44/75 (58.7) | 46.7–69.9 |
| A247T | S83C | 0/1 | 0/1 | 0/2 (0) | ||
| G248A | S83N | 0/3 | 0/3 (0) | |||
| G259A | D87N | 0/1 | 1/12 | 1/4 | 2/17 (11.8) | 1.5–36.4 |
| A260G | D87G | 0/1 | 0/1 (0) | |||
| G259T | D87Y | 1/4 | 1/4 (25.0) | 0.6–80.6 | ||
| No change | Absence of S83/D87 (WT) | 0/44 | 4/151 | 2/78 | 6/273 (2.2) | 0.8–4.7 |
| Absence of G248T | Absence of S83I | 2/47 | 5/171 | 5/88 | 11/306 (3.6) | 1.9–6.4 |
a
A total of 321 samples were sequenced from the 2016 to 2018 group, but only 201 patients were treated with moxifloxacin (the remainder were treated with sitafloxacin). SNP, single nucleotide polymorphism.
b
For this study group, pretreatment samples were not available for 2 patients, so posttreatment sequences were used.
c
Additionally, there was one patient with a parC G241A/G81S variant in the 2016 to 2018 time period; this was successfully treated with moxifloxacin.